Article · Wikipedia archive · Last revised Aug 5, 2026

Fexlamose

Fexlamose is an investigational new drug that is being developed by Aer Therapeutics for the treatment of chronic obstructive pulmonary disease. It is mucolytic agent that contains a thiol linked to a saccharide that undergoes thiol–disulfide exchange with mucin disulfide bridges thereby breaking those bonds between mucin subunits and reducing the viscosity of mucin.

Last revised
Aug 5, 2026
Read time
≈ 1 min
Length
117 w
Citations
2
Source
Wikipedia ↗
Fexlamose
Clinical data
Other namesAER-01; MUC-031
Identifiers
  • (2S,3S,4S,5R,6R)-2-(sulfanylmethyl)-6-[(2R,3R,4S,5S,6S)-3,4,5-trihydroxy-6-(sulfanylmethyl)oxan-2-yl]oxyoxane-3,4,5-triol
CAS Number
PubChem CID
ChemSpider
UNII
Chemical and physical data
FormulaC12H22O9S2
Molar mass374.42 g·mol−1
3D model (JSmol)
  • C([C@@H]1[C@H]([C@@H]([C@H]([C@H](O1)O[C@@H]2[C@@H]([C@H]([C@@H]([C@H](O2)CS)O)O)O)O)O)O)S
  • InChI=InChI=1S/C12H22O9S2/c13-5-3(1-22)19-11(9(17)7(5)15)21-12-10(18)8(16)6(14)4(2-23)20-12/h3-18,22-23H,1-2H2/t3-,4-,5-,6-,7+,8+,9-,10-,11-,12-/m1/s1
  • Key:LVLYFBOCRJBHIZ-LIZSDCNHSA-N

Fexlamose is an investigational new drug that is being developed by Aer Therapeutics for the treatment of chronic obstructive pulmonary disease. It is mucolytic agent that contains a thiol linked to a saccharide that undergoes thiol–disulfide exchange with mucin disulfide bridges thereby breaking those bonds between mucin subunits and reducing the viscosity of mucin.12

References

References

  1. "Fexlamose". AdisInsight. Springer Nature Switzerland AG. Retrieved 3 July 2026.
  2. Cazzola M, Rogliani P, Ora J, Calzetta L, Matera MG (April 2026). "Mucus as a Treatable Trait in Chronic Airway Diseases". Drugs. 86 (4): 443–463. doi:10.1007/s40265-026-02294-1. PMC 13005781. PMID 41712061.